(Reuters) - WASHINGTON, June 27 - A U.S. Senate panel voted
on Wednesday to set a path for generic drugmakers to seek
approval of cheaper, copycat versions of expensive
biotechnology medicines.
Brand-name manufacturers would receive 12 years of
exclusive marketing time before generic competition could start
under a bill that cleared the Senate Health, Education, Labor
and Pensions Committee by a voice vote.
Read more at Reuters.com Government Filings News
on Wednesday to set a path for generic drugmakers to seek
approval of cheaper, copycat versions of expensive
biotechnology medicines.
Brand-name manufacturers would receive 12 years of
exclusive marketing time before generic competition could start
under a bill that cleared the Senate Health, Education, Labor
and Pensions Committee by a voice vote.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment